Matches in SemOpenAlex for { <https://semopenalex.org/work/W2411643300> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W2411643300 endingPage "73" @default.
- W2411643300 startingPage "165" @default.
- W2411643300 abstract "Isepamicin is a new aminoglycoside antibiotic which possesses greater stability to aminoglycoside-inactivating enzymes compared with other available aminoglycosides. In this prospective, randomised, open trial, the safety and efficacy of intravenous administration of isepamicin was compared with that of intravenous amikacin in seriously ill adults with nosocomial pneumonia or septicaemia. Each study aminoglycoside was administered concurrently with ceftazidime or imipenem. Patients were randomised to receive isepamicin 15 mg/kg once daily, isepamicin 7.5 mg/kg twice daily or amikacin 7.5 mg/kg twice daily. For patients with nosocomial pneumonia, the proportions of patients in the intent-to-treat population (n = 130) who were clinically cured at the end of treatment were similar in each treatment group: 18/44 (41%) isepamicin once daily; 19/45 (42%) isepamicin twice daily; and 17/41 (42%) amikacin. Corresponding results for the efficacy population (n = 58) were: 12/20 (60%) isepamicin once daily; 14/21 (67%) isepamicin twice daily; 9/17 (53%) amikacin. In patients with septicaemia, clinical cure was achieved in 8/10 (80%) patients treated with isepamicin once daily, compared with 8/13 (62%) patients who received isepamicin twice daily, and 7/12 (58%) patients treated with amikacin. For both diagnoses, there were no statistically significant differences between the treatment groups in clinical cure rate. The most commonly isolated target pathogen was Pseudomonas aeruginosa. For both nosocomial pneumonia and septicaemia, the proportion of patients in the intent-to-treat population whose pretreatment valid target pathogens were eliminated was similar in each treatment group. In total, 51 patients (30%) died during study, mostly due to disease progression or complications, or concurrent illness. All three treatment regimens were well tolerated. The proportion of patients experiencing at least one adverse event was 11%, 25% and 9% for isepamicin once daily, isepamicin twice daily and amikacin, respectively. The incidence of ototoxicity and nephrotoxicity was relatively low in both treatment groups." @default.
- W2411643300 created "2016-06-24" @default.
- W2411643300 creator A5017789185 @default.
- W2411643300 date "1995-06-01" @default.
- W2411643300 modified "2023-09-23" @default.
- W2411643300 title "Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia." @default.
- W2411643300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8904144" @default.
- W2411643300 hasPublicationYear "1995" @default.
- W2411643300 type Work @default.
- W2411643300 sameAs 2411643300 @default.
- W2411643300 citedByCount "8" @default.
- W2411643300 countsByYear W24116433002013 @default.
- W2411643300 crossrefType "journal-article" @default.
- W2411643300 hasAuthorship W2411643300A5017789185 @default.
- W2411643300 hasConcept C126322002 @default.
- W2411643300 hasConcept C141071460 @default.
- W2411643300 hasConcept C2777427914 @default.
- W2411643300 hasConcept C2777787772 @default.
- W2411643300 hasConcept C2777914695 @default.
- W2411643300 hasConcept C2908647359 @default.
- W2411643300 hasConcept C3019249092 @default.
- W2411643300 hasConcept C501593827 @default.
- W2411643300 hasConcept C71924100 @default.
- W2411643300 hasConcept C86803240 @default.
- W2411643300 hasConcept C89423630 @default.
- W2411643300 hasConcept C99454951 @default.
- W2411643300 hasConceptScore W2411643300C126322002 @default.
- W2411643300 hasConceptScore W2411643300C141071460 @default.
- W2411643300 hasConceptScore W2411643300C2777427914 @default.
- W2411643300 hasConceptScore W2411643300C2777787772 @default.
- W2411643300 hasConceptScore W2411643300C2777914695 @default.
- W2411643300 hasConceptScore W2411643300C2908647359 @default.
- W2411643300 hasConceptScore W2411643300C3019249092 @default.
- W2411643300 hasConceptScore W2411643300C501593827 @default.
- W2411643300 hasConceptScore W2411643300C71924100 @default.
- W2411643300 hasConceptScore W2411643300C86803240 @default.
- W2411643300 hasConceptScore W2411643300C89423630 @default.
- W2411643300 hasConceptScore W2411643300C99454951 @default.
- W2411643300 hasLocation W24116433001 @default.
- W2411643300 hasOpenAccess W2411643300 @default.
- W2411643300 hasPrimaryLocation W24116433001 @default.
- W2411643300 hasRelatedWork W1535976727 @default.
- W2411643300 hasRelatedWork W2029413694 @default.
- W2411643300 hasRelatedWork W2091556442 @default.
- W2411643300 hasRelatedWork W2341940401 @default.
- W2411643300 hasRelatedWork W2396383686 @default.
- W2411643300 hasRelatedWork W2444316827 @default.
- W2411643300 hasRelatedWork W2993238898 @default.
- W2411643300 hasRelatedWork W2994715795 @default.
- W2411643300 hasRelatedWork W808843618 @default.
- W2411643300 hasRelatedWork W2460882367 @default.
- W2411643300 hasVolume "7 Suppl 2" @default.
- W2411643300 isParatext "false" @default.
- W2411643300 isRetracted "false" @default.
- W2411643300 magId "2411643300" @default.
- W2411643300 workType "article" @default.